Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells
NCT ID: NCT05108077
Last Updated: 2022-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
20 participants
INTERVENTIONAL
2022-03-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Recurrent Bladder Cancer With Dendritic Cells
NCT04184232
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
NCT01328574
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
NCT00981656
CIK in Treating Patients With Bladder Cancer
NCT02489890
An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer
NCT05559177
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cytokine-induced killer cells
Patients with the metastatic tumors of the urogenital area receiving standard treatment and autologous cytokine-induced killer cells
cytokine-induced killer cells
Autologous cytokine-induced killer cells injected intravenously
Standard treatment according to the Clinical protocols
Standard treatment of bladder/renal cancer according to the Clinical protocols
Control
Patients with metastatic tumors of the urogenital area receiving standard treatment
Standard treatment according to the Clinical protocols
Standard treatment of bladder/renal cancer according to the Clinical protocols
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cytokine-induced killer cells
Autologous cytokine-induced killer cells injected intravenously
Standard treatment according to the Clinical protocols
Standard treatment of bladder/renal cancer according to the Clinical protocols
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient who require repetitive transurethral resection;
* Expression of muc-1/wt-1 by the tumor;
* EGOC 0-3;
Exclusion Criteria
* pregnancy/lactation;
* chronic infections, including hepatitis B/C, tuberculosis, HIV
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Belarusian State Medical University
OTHER
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrei Hancharou
Role: STUDY_DIRECTOR
the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Alexander Prokhorov, Dr
Role: STUDY_DIRECTOR
Belarusian State Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Minsk, , Belarus
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IBCE_CIK
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.